Castera L

20 publications in the catalogue · 2006–2023 · 8 as first author

20 publications

Diseases

  1. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  2. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021

    FibroTest NashTest-2 SteatoTest Metabolic

  3. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  4. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017

    FibroTest Other

  5. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015

    FibroTest HBV HCV

  6. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.

    Castera L et al. · HIV Med · 2014

    FibroTest HCV HIV

  7. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014

    FibroTest HBV HCV

  8. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013

    ActiTest FibroTest NashTest SteatoTest +1

  9. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013

    ActiTest FibroTest HCV

  10. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2012

    FibroTest HCV

  11. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011

    FibroTest HBV HCV HIV +1

  12. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

    Poynard T et al. · Gastroenterol Clin Biol · 2010

    ActiTest HCV

  13. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010

    FibroTest Alcohol HBV HCV +1

  14. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009

    FibroTest HCV

  15. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009

    FibroTest HBV HCV HIV

  16. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

    Castera L et al. · J Hepatol · 2007

    FibroTest HCV

  17. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007

    FibroTest Alcohol HBV HCV +1

  18. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication

    Poynard T et al. · Clin Chem · 2007

    FibroTest HCV

  19. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

    Poynard T et al. · Aliment Pharmacol Ther · 2007

    FibroTest HCV

  20. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.

    Castera L et al. · Hepatology · 2006

    FibroTest HCV